HTT and Huntington disease: Screening for biologically active molecules that inhibit polyglutamine aggregation, lead to the identification of a pharmacological ROCK inhibitor, Y-27632 [21], [22] When Y-27632 was administrated in a Drosophila model of HD, it reduced Htt-exon1 (93Q) induced neurodegeneration.